Reviews Gengraf Oral Solution


No reviews yet.

Gengraf Oral Solution Drug Description
GENGRAF® Oral Solution
(cyclosporine) Oral Solution, USP [MODIFIED]

WARNING
Only physicians experienced in the management of systemic
immunosuppressive therapy for the indicated disease should prescribe Gengraf®
(cyclosporine oral solution, USP [MODIFIED]). At doses used in solid
organ transplantation, only physicians experienced in immunosuppressive therapy
and management of organ transplant recipients should prescribe Gengraf®.
Patients receiving the drug should be managed in facilities equipped and
staffed with adequate laboratory and supportive medical resources. The
physician responsible for maintenance therapy should have complete information
requisite for the follow-up of the patient.
Gengraf®, a systemic immunosuppressant, may increase the
susceptibility to infection and the development of neoplasia. In kidney, liver,
and heart transplant patients Gengraf® may be administered with other
immunosuppressive agents. Increased susceptibility to infection and the
possible development of lymphoma and other neoplasms may result from the
increase in the degree of immunosuppression in transplant patients.


Gengraf® (cyclosporine oral solution, USP [MODIFIED])
has increased bioavailability in comparison to Sandimmune®* (cyclosporine oral
solution, USP [Non-Modified]). Gengraf® and Sandimmune®* are not bioequivalent
and cannot be used interchangeably without physician supervision. For a given
trough concentration, cyclosporine exposure will be greater with Gengraf® than
with Sandimmune®*. If a patient who is receiving exceptionally high doses of
Sandimmune®* is converted to Gengraf®, particular caution should be exercised. Cyclosporine
blood concentrations should be monitored in transplant and rheumatoid arthritis
patients taking Gengraf® to avoid toxicity due to high concentrations. Dose
adjustments should be made in transplant patients to minimize possible organ
rejection due to low concentrations. Comparison of blood concentrations in the
published literature with blood concentrations obtained using current assays
must be done with detailed knowledge of the assay methods employed.


For Psoriasis Patients (see also BOXED WARNINGS above)
Psoriasis patients previously treated with PUVA and to a
lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar,
or radiation therapy, are at an increased risk of developing skin malignancies
when taking Gengraf® (cyclosporine oral solution, USP [MODIFIED]).
Cyclosporine, the active ingredient in Gengraf®, in
recommended dosages, can cause systemic hypertension and nephrotoxicity. The
risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of
cyclosporine, and therefore, renal function must be monitored during therapy.

DRUG DESCRIPTION



What are the possible side effects of cyclosporine (Gengraf, Neoral, Sandimmune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst;
swelling, weight gain, feeling short of breath;
blurred vision, headache or pain behind your eyes, sometimes...
Read All Potential Side Effects for Gengraf Oral Solution »




Gengraf® (cyclosporine oral solution, USP [MODIFIED]) is a
modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment.
Cyclosporine, the active principle in Gengraf® Oral
Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite by the
fungus species Aphanocladium album.
Chemically, cyclosporine is designated as [R-[R*,
R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-Lleucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-α-amino-butyryl-N-methylglycyl-N-methyl-Lleucyl-L-valyl-N-methyl-L-leucyl).
Gengraf® Oral Solution (cyclosporine oral solution, USP
[MODIFIED]) is available in 50 mL bottles. Each mL contains: cyclosporine 100 mg/mL.
Inactive Ingredients: Polyoxyl 40 hydrogenated castor oil NF,
propylene glycol USP, sorbitan monooleate NF.
The chemical structure for cyclosporine USP is:








Last reviewed on RxList: 5/7/2009




Gengraf Oral Solution Drug Description
GENGRAF® Oral Solution
(cyclosporine) Oral Solution, USP [MODIFIED]

WARNING
Only physicians experienced in the management of systemic
immunosuppressive therapy for the indicated disease should prescribe Gengraf®
(cyclosporine oral solution, USP [MODIFIED]). At doses used in solid
organ transplantation, only physicians experienced in immunosuppressive therapy
and management of organ transplant recipients should prescribe Gengraf®.
Patients receiving the drug should be managed in facilities equipped and
staffed with adequate laboratory and supportive medical resources. The
physician responsible for maintenance therapy should have complete information
requisite for the follow-up of the patient.
Gengraf®, a systemic immunosuppressant, may increase the
susceptibility to infection and the development of neoplasia. In kidney, liver,
and heart transplant patients Gengraf® may be administered with other
immunosuppressive agents. Increased susceptibility to infection and the
possible development of lymphoma and other neoplasms may result from the
increase in the degree of immunosuppression in transplant patients.


Gengraf® (cyclosporine oral solution, USP [MODIFIED])
has increased bioavailability in comparison to Sandimmune®* (cyclosporine oral
solution, USP [Non-Modified]). Gengraf® and Sandimmune®* are not bioequivalent
and cannot be used interchangeably without physician supervision. For a given
trough concentration, cyclosporine exposure will be greater with Gengraf® than
with Sandimmune®*. If a patient who is receiving exceptionally high doses of
Sandimmune®* is converted to Gengraf®, particular caution should be exercised. Cyclosporine
blood concentrations should be monitored in transplant and rheumatoid arthritis
patients taking Gengraf® to avoid toxicity due to high concentrations. Dose
adjustments should be made in transplant patients to minimize possible organ
rejection due to low concentrations. Comparison of blood concentrations in the
published literature with blood concentrations obtained using current assays
must be done with detailed knowledge of the assay methods employed.


For Psoriasis Patients (see also BOXED WARNINGS above)
Psoriasis patients previously treated with PUVA and to a
lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar,
or radiation therapy, are at an increased risk of developing skin malignancies
when taking Gengraf® (cyclosporine oral solution, USP [MODIFIED]).
Cyclosporine, the active ingredient in Gengraf®, in
recommended dosages, can cause systemic hypertension and nephrotoxicity. The
risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of
cyclosporine, and therefore, renal function must be monitored during therapy.

DRUG DESCRIPTION



What are the possible side effects of cyclosporine (Gengraf, Neoral, Sandimmune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst;
swelling, weight gain, feeling short of breath;
blurred vision, headache or pain behind your eyes, sometimes...
Read All Potential Side Effects for Gengraf Oral Solution »




Gengraf® (cyclosporine oral solution, USP [MODIFIED]) is a
modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment.
Cyclosporine, the active principle in Gengraf® Oral
Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite by the
fungus species Aphanocladium album.
Chemically, cyclosporine is designated as [R-[R*,
R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-Lleucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-α-amino-butyryl-N-methylglycyl-N-methyl-Lleucyl-L-valyl-N-methyl-L-leucyl).
Gengraf® Oral Solution (cyclosporine oral solution, USP
[MODIFIED]) is available in 50 mL bottles. Each mL contains: cyclosporine 100 mg/mL.
Inactive Ingredients: Polyoxyl 40 hydrogenated castor oil NF,
propylene glycol USP, sorbitan monooleate NF.
The chemical structure for cyclosporine USP is:








Last reviewed on RxList: 5/7/2009




Gengraf Oral Solution Drug Description
GENGRAF® Oral Solution
(cyclosporine) Oral Solution, USP [MODIFIED]

WARNING
Only physicians experienced in the management of systemic
immunosuppressive therapy for the indicated disease should prescribe Gengraf®
(cyclosporine oral solution, USP [MODIFIED]). At doses used in solid
organ transplantation, only physicians experienced in immunosuppressive therapy
and management of organ transplant recipients should prescribe Gengraf®.
Patients receiving the drug should be managed in facilities equipped and
staffed with adequate laboratory and supportive medical resources. The
physician responsible for maintenance therapy should have complete information
requisite for the follow-up of the patient.
Gengraf®, a systemic immunosuppressant, may increase the
susceptibility to infection and the development of neoplasia. In kidney, liver,
and heart transplant patients Gengraf® may be administered with other
immunosuppressive agents. Increased susceptibility to infection and the
possible development of lymphoma and other neoplasms may result from the
increase in the degree of immunosuppression in transplant patients.


Gengraf® (cyclosporine oral solution, USP [MODIFIED])
has increased bioavailability in comparison to Sandimmune®* (cyclosporine oral
solution, USP [Non-Modified]). Gengraf® and Sandimmune®* are not bioequivalent
and cannot be used interchangeably without physician supervision. For a given
trough concentration, cyclosporine exposure will be greater with Gengraf® than
with Sandimmune®*. If a patient who is receiving exceptionally high doses of
Sandimmune®* is converted to Gengraf®, particular caution should be exercised. Cyclosporine
blood concentrations should be monitored in transplant and rheumatoid arthritis
patients taking Gengraf® to avoid toxicity due to high concentrations. Dose
adjustments should be made in transplant patients to minimize possible organ
rejection due to low concentrations. Comparison of blood concentrations in the
published literature with blood concentrations obtained using current assays
must be done with detailed knowledge of the assay methods employed.


For Psoriasis Patients (see also BOXED WARNINGS above)
Psoriasis patients previously treated with PUVA and to a
lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar,
or radiation therapy, are at an increased risk of developing skin malignancies
when taking Gengraf® (cyclosporine oral solution, USP [MODIFIED]).
Cyclosporine, the active ingredient in Gengraf®, in
recommended dosages, can cause systemic hypertension and nephrotoxicity. The
risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of
cyclosporine, and therefore, renal function must be monitored during therapy.

DRUG DESCRIPTION



What are the possible side effects of cyclosporine (Gengraf, Neoral, Sandimmune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst;
swelling, weight gain, feeling short of breath;
blurred vision, headache or pain behind your eyes, sometimes...
Read All Potential Side Effects for Gengraf Oral Solution »




Gengraf® (cyclosporine oral solution, USP [MODIFIED]) is a
modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment.
Cyclosporine, the active principle in Gengraf® Oral
Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite by the
fungus species Aphanocladium album.
Chemically, cyclosporine is designated as [R-[R*,
R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-Lleucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-α-amino-butyryl-N-methylglycyl-N-methyl-Lleucyl-L-valyl-N-methyl-L-leucyl).
Gengraf® Oral Solution (cyclosporine oral solution, USP
[MODIFIED]) is available in 50 mL bottles. Each mL contains: cyclosporine 100 mg/mL.
Inactive Ingredients: Polyoxyl 40 hydrogenated castor oil NF,
propylene glycol USP, sorbitan monooleate NF.
The chemical structure for cyclosporine USP is:








Last reviewed on RxList: 5/7/2009




Gengraf Oral Solution Drug Description
GENGRAF® Oral Solution
(cyclosporine) Oral Solution, USP [MODIFIED]

WARNING
Only physicians experienced in the management of systemic
immunosuppressive therapy for the indicated disease should prescribe Gengraf®
(cyclosporine oral solution, USP [MODIFIED]). At doses used in solid
organ transplantation, only physicians experienced in immunosuppressive therapy
and management of organ transplant recipients should prescribe Gengraf®.
Patients receiving the drug should be managed in facilities equipped and
staffed with adequate laboratory and supportive medical resources. The
physician responsible for maintenance therapy should have complete information
requisite for the follow-up of the patient.
Gengraf®, a systemic immunosuppressant, may increase the
susceptibility to infection and the development of neoplasia. In kidney, liver,
and heart transplant patients Gengraf® may be administered with other
immunosuppressive agents. Increased susceptibility to infection and the
possible development of lymphoma and other neoplasms may result from the
increase in the degree of immunosuppression in transplant patients.


Gengraf® (cyclosporine oral solution, USP [MODIFIED])
has increased bioavailability in comparison to Sandimmune®* (cyclosporine oral
solution, USP [Non-Modified]). Gengraf® and Sandimmune®* are not bioequivalent
and cannot be used interchangeably without physician supervision. For a given
trough concentration, cyclosporine exposure will be greater with Gengraf® than
with Sandimmune®*. If a patient who is receiving exceptionally high doses of
Sandimmune®* is converted to Gengraf®, particular caution should be exercised. Cyclosporine
blood concentrations should be monitored in transplant and rheumatoid arthritis
patients taking Gengraf® to avoid toxicity due to high concentrations. Dose
adjustments should be made in transplant patients to minimize possible organ
rejection due to low concentrations. Comparison of blood concentrations in the
published literature with blood concentrations obtained using current assays
must be done with detailed knowledge of the assay methods employed.


For Psoriasis Patients (see also BOXED WARNINGS above)
Psoriasis patients previously treated with PUVA and to a
lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar,
or radiation therapy, are at an increased risk of developing skin malignancies
when taking Gengraf® (cyclosporine oral solution, USP [MODIFIED]).
Cyclosporine, the active ingredient in Gengraf®, in
recommended dosages, can cause systemic hypertension and nephrotoxicity. The
risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of
cyclosporine, and therefore, renal function must be monitored during therapy.

DRUG DESCRIPTION



What are the possible side effects of cyclosporine (Gengraf, Neoral, Sandimmune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst;
swelling, weight gain, feeling short of breath;
blurred vision, headache or pain behind your eyes, sometimes...
Read All Potential Side Effects for Gengraf Oral Solution »




Gengraf® (cyclosporine oral solution, USP [MODIFIED]) is a
modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment.
Cyclosporine, the active principle in Gengraf® Oral
Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite by the
fungus species Aphanocladium album.
Chemically, cyclosporine is designated as [R-[R*,
R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-Lleucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-α-amino-butyryl-N-methylglycyl-N-methyl-Lleucyl-L-valyl-N-methyl-L-leucyl).
Gengraf® Oral Solution (cyclosporine oral solution, USP
[MODIFIED]) is available in 50 mL bottles. Each mL contains: cyclosporine 100 mg/mL.
Inactive Ingredients: Polyoxyl 40 hydrogenated castor oil NF,
propylene glycol USP, sorbitan monooleate NF.
The chemical structure for cyclosporine USP is:








Last reviewed on RxList: 5/7/2009




Gengraf Oral Solution Drug Description
GENGRAF® Oral Solution
(cyclosporine) Oral Solution, USP [MODIFIED]

WARNING
Only physicians experienced in the management of systemic
immunosuppressive therapy for the indicated disease should prescribe Gengraf®
(cyclosporine oral solution, USP [MODIFIED]). At doses used in solid
organ transplantation, only physicians experienced in immunosuppressive therapy
and management of organ transplant recipients should prescribe Gengraf®.
Patients receiving the drug should be managed in facilities equipped and
staffed with adequate laboratory and supportive medical resources. The
physician responsible for maintenance therapy should have complete information
requisite for the follow-up of the patient.
Gengraf®, a systemic immunosuppressant, may increase the
susceptibility to infection and the development of neoplasia. In kidney, liver,
and heart transplant patients Gengraf® may be administered with other
immunosuppressive agents. Increased susceptibility to infection and the
possible development of lymphoma and other neoplasms may result from the
increase in the degree of immunosuppression in transplant patients.


Gengraf® (cyclosporine oral solution, USP [MODIFIED])
has increased bioavailability in comparison to Sandimmune®* (cyclosporine oral
solution, USP [Non-Modified]). Gengraf® and Sandimmune®* are not bioequivalent
and cannot be used interchangeably without physician supervision. For a given
trough concentration, cyclosporine exposure will be greater with Gengraf® than
with Sandimmune®*. If a patient who is receiving exceptionally high doses of
Sandimmune®* is converted to Gengraf®, particular caution should be exercised. Cyclosporine
blood concentrations should be monitored in transplant and rheumatoid arthritis
patients taking Gengraf® to avoid toxicity due to high concentrations. Dose
adjustments should be made in transplant patients to minimize possible organ
rejection due to low concentrations. Comparison of blood concentrations in the
published literature with blood concentrations obtained using current assays
must be done with detailed knowledge of the assay methods employed.


For Psoriasis Patients (see also BOXED WARNINGS above)
Psoriasis patients previously treated with PUVA and to a
lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar,
or radiation therapy, are at an increased risk of developing skin malignancies
when taking Gengraf® (cyclosporine oral solution, USP [MODIFIED]).
Cyclosporine, the active ingredient in Gengraf®, in
recommended dosages, can cause systemic hypertension and nephrotoxicity. The
risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of
cyclosporine, and therefore, renal function must be monitored during therapy.

DRUG DESCRIPTION



What are the possible side effects of cyclosporine (Gengraf, Neoral, Sandimmune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst;
swelling, weight gain, feeling short of breath;
blurred vision, headache or pain behind your eyes, sometimes...
Read All Potential Side Effects for Gengraf Oral Solution »




Gengraf® (cyclosporine oral solution, USP [MODIFIED]) is a
modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment.
Cyclosporine, the active principle in Gengraf® Oral
Solution, is a cyclic polypeptide immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite by the
fungus species Aphanocladium album.
Chemically, cyclosporine is designated as [R-[R*,
R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-Lleucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-α-amino-butyryl-N-methylglycyl-N-methyl-Lleucyl-L-valyl-N-methyl-L-leucyl).
Gengraf® Oral Solution (cyclosporine oral solution, USP
[MODIFIED]) is available in 50 mL bottles. Each mL contains: cyclosporine 100 mg/mL.
Inactive Ingredients: Polyoxyl 40 hydrogenated castor oil NF,
propylene glycol USP, sorbitan monooleate NF.
The chemical structure for cyclosporine USP is:








Last reviewed on RxList: 5/7/2009





Other reviews about Gengraf Oral Solution on wordpress

Americans Need Help Getting Meds- How to Get Free or Reduced Needed RX medications
  by paganmedia
Thanks to USA federal government incentives, pharmaceutical companies may provide free prescription medicines if : Sourced and Submitted: By Lady Paradise ~ With much appreciated thanks on this […]


but before she could
  by czjupmosysajorn
I dont want any of her old pears and things; my cooking will turn out well, and Ill have a splendid dinner; see if I dont! Her voice […]


But he has learned to l
  by acapyhldgev
But after all, thats thirty thousand roubles. Dillon, exlord mayor of Dublin. With a whaleboat towing for steerage and as a precaution against backdraughts from the cliff, and […]


The dying Englishman smiled
  by jkildeljitbprv


Anyway, if you we fill up the sp
  by udsidptlbdpzljq
There is no originality in them whatever. It was the first time he had thought of Bowers in years, and it did nothing for his peace of mind. […]


Supposing that discover
  by owsaswyhrocu
Well, child, how would you like to take a voyage round the world with me in a jolly old craft like this? Im going upcountry with a column, […]


Supposing that discover
  by owsaswyhrocu
Well, child, how would you like to take a voyage round the world with me in a jolly old craft like this? Im going upcountry with a column, […]


You and I, Emma, will
  by zsrymabhhfmepp
If not, well sell em for the charges. What the writer had felt, what she had imagined, what she had desired, was all set out, frequently in but […]


Youll please yourselves, she s
  by kqzxqkkjssl
I earnestly pressed his coming to us, and should not be surprised to see him walk in today or tomorrow, or any day. There is always something offensive […]


With his head hunched low he travelled
  by fyvroxevivyhp
I will suppose it to be one of those afternoons, when all has gone smoothly and pleasantly, in school. Feels like it was full of gold bricks. When […]



Other reviews about Gengraf Oral Solution on web:

Learn about the prescription medication Gengraf Oral Solution (Cyclosporine Oral Solution), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling. Gengraf Oral Solution (Cyclosporine Oral Solution) Drug ...


The effect of milk on the bioavailability of cyclosporine when administered as Gengraf Oral Solution has not been evaluated. The relationship between administered dose and exposure ... Gengraf Official FDA information, side effects and uses.


Learn about Gengraf Oral Solution (Cyclosporine Oral Solution) - Side Effects, Drug Interactions, Pictures, Patient Information on RxList Gengraf Oral Solution (Cyclosporine Oral Solution) Patient Drug ...


Find patient medical information for Gengraf Oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Gengraf Oral : Uses, Side Effects, Interactions, Pictures ...


Comprehensive and accurate Gengraf Oral Solution side effects information for consumers and healthcare professionals. Gengraf Oral Solution Side Effects | Drugs.com


Learn about Gengraf Oral - its uses, dosage, side effects, drug interactions, and safety information on RxList. Gengraf Oral Drug information on Uses, Side Effects, Interactions ...


Gengraf (cyclosporine oral solution, USP ) ... Gengraf


Gengraf ... To Improve The Taste Of The Oral Solution, Dilute It With Orange, Apple, Or Cranberry Juice. GENGRAF Patient Assistance Program


Attention, chocolate lovers: You may not be able to help yourselves. Swiss and British scientists have linked the widespread love of chocolate to a chemical "signature" that may be ... GENGRAF ORAL SOLUTION (cyclosporine oral solution USP [MODIFIED ...


Buy Cyclosporine oral solution - 100 mg/mL: Buy Gengraf - 25 mg: View other items in this category: Immunosuppressant Medications and Products Buy Cheap Online Cyclosporine Oral Solution





Featured Reviews

Reviews Vyvanse

Vyvanse Drug Description Vyvanse® (lisdexamfetamine dimesylate) Capsules WARNING: POTENTIAL FOR ABUSE AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG...
Read More  |  Review This
Reviews Dutasteride

Duagen Drug Description Duagen (dutasteride)Soft Gelatin Capsules DRUG DESCRIPTION Duagen (dutasteride) is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5α-reductase...
Read More  |  Review This
Reviews Flagyl Injection

Flagyl Injection Drug Description Metronidazole Injection, USP RTU® in Plastic Container VIAFLEX Plus Container To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection, USP RTU®...
Read More  |  Review This
Reviews Hepsera

Hepsera Drug Description HEPSERA (adefovir dipivoxil) Tablets WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS, NEPHROTOXICITY, HIV RESISTANCE, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS Severe acute exacerbations of...
Read More  |  Review This
Reviews Aminosyn II in Dextrose

Aminosyn II in Dextrose Drug Description Aminosyn® II in Dextrose Injection AN AMINO ACID INJECTION IN DEXTROSE INJECTION NOTE: These solutions are hypertonic. See WARNINGS and PRECAUTIONS. Nutrimix® Dual-chamber Flexible...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....